Pila Pharma AB (ST:PILA) — Market Cap & Net Worth
Market Cap & Net Worth: Pila Pharma AB (PILA)
Pila Pharma AB (ST:PILA) has a market capitalization of $9.12 Million (Skr84.74 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27411 globally and #599 in its home market, demonstrating a -14.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pila Pharma AB's stock price Skr1.86 by its total outstanding shares 45682121 (45.68 Million). Also see Pila Pharma AB asset portfolio for a full breakdown of the balance sheet.
Pila Pharma AB Market Cap History: 2021 to 2026
Pila Pharma AB's market capitalization history from 2021 to 2026. Data shows change from $33.43 Million to $9.12 Million (-26.23% CAGR). Also see Pila Pharma AB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Pila Pharma AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.23 Billion | 0.06% | #166 of 281 |
Weight: Pila Pharma AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pila Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pila Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Pila Pharma AB (PILA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.99x
Pila Pharma AB's market cap is 8.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $33.43 Million | $719.23K | -$17.21 Million | 46.48x | N/A |
| 2022 | $15.22 Million | $1.88 Million | -$26.78 Million | 8.09x | N/A |
| 2023 | $7.87 Million | $1.46 Million | -$9.93 Million | 5.38x | N/A |
| 2024 | $18.44 Million | $775.00K | -$11.24 Million | 23.79x | N/A |
| 2025 | $10.13 Million | $1.13 Million | -$16.86 Million | 8.99x | N/A |
Competitor Companies of PILA by Market Capitalization
Companies near Pila Pharma AB in the global market cap rankings as of September 19, 2026. Review Pila Pharma AB (PILA) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pila Pharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Pila Pharma AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Pila Pharma AB's market cap moved from $33.43 Million to $ 9.12 Million, with a yearly change of -26.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr9.12 Million | -9.95% |
| 2025 | Skr10.13 Million | -45.07% |
| 2024 | Skr18.44 Million | +134.38% |
| 2023 | Skr7.87 Million | -48.30% |
| 2022 | Skr15.22 Million | -54.49% |
| 2021 | Skr33.43 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Pila Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.12 Million USD |
| MoneyControl | $9.12 Million USD |
| MarketWatch | $9.12 Million USD |
| marketcap.company | $9.12 Million USD |
| Reuters | $9.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pila Pharma AB
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is hea… Read more